Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin dose requirements in a patient with the CYP2C9*14 allele.

Pharmacogenomics - 1 May 2014

Lee Yee Ming, Eggen Jessica, Soni Vinay, Drozda Katarzyna, Nutescu Edith A, Cavallari Larisa H

Abstract excerpt

We describe a 64-year-old male of Indian descent with a history of atrial fibrillation who was started on warfarin after hospital admission for acute stroke. He received genotype-guided warfarin dosing as per the standard-of-care at our hospital, with daily dose recommendations provided by the pharmacogenetics service. Genotyping revealed the rare CYP2C9*1/*14 genotype and warfarin insensitive VKORC1 -1639GG and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Atrial Fibrillation
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to VKORC1 gene

Share to Genotype

Share to Stroke

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 24956244
DOI: 10.2217/pgs.14.47
PMCID: PMC4151614

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin dose requirements in a patient with the CYP2C9*14 allele.PMID 24956244Read ↗

Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.Semantic proximity Read ↗

Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response.Semantic proximity Read ↗

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population.Semantic proximity Read ↗

Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype distribution in Asian countries.Semantic proximity Read ↗

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.